NO963806L - Rekombinante viruser som koder for en glutamat-dekarboksylase (GAD)aktivitet - Google Patents
Rekombinante viruser som koder for en glutamat-dekarboksylase (GAD)aktivitetInfo
- Publication number
- NO963806L NO963806L NO963806A NO963806A NO963806L NO 963806 L NO963806 L NO 963806L NO 963806 A NO963806 A NO 963806A NO 963806 A NO963806 A NO 963806A NO 963806 L NO963806 L NO 963806L
- Authority
- NO
- Norway
- Prior art keywords
- gad
- activity
- virus
- glutamate decarboxylase
- contg
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 5
- 102000008214 Glutamate decarboxylase Human genes 0.000 title abstract 4
- 108091022930 Glutamate decarboxylase Proteins 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
- 108091092584 GDNA Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 210000002744 extracellular matrix Anatomy 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9403411A FR2717823B1 (fr) | 1994-03-23 | 1994-03-23 | Virus recombinants, préparation et utilisation en thérapie génique. |
FR9413487A FR2726575B1 (fr) | 1994-11-09 | 1994-11-09 | Virus recombinants, preparation et utilisation en therapie genique |
PCT/FR1995/000342 WO1995025805A1 (fr) | 1994-03-23 | 1995-03-21 | Virus recombinants codant pour une activite glutamate decarboxylase (gad) |
Publications (2)
Publication Number | Publication Date |
---|---|
NO963806D0 NO963806D0 (no) | 1996-09-11 |
NO963806L true NO963806L (no) | 1996-09-11 |
Family
ID=26231035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO963806A NO963806L (no) | 1994-03-23 | 1996-09-11 | Rekombinante viruser som koder for en glutamat-dekarboksylase (GAD)aktivitet |
Country Status (13)
Country | Link |
---|---|
US (1) | US20020028212A1 (no) |
EP (2) | EP1681354A3 (no) |
JP (1) | JPH09511394A (no) |
KR (1) | KR100403893B1 (no) |
AT (1) | ATE320502T1 (no) |
AU (1) | AU2140695A (no) |
CA (1) | CA2184297C (no) |
DE (1) | DE69534873T2 (no) |
FI (1) | FI963755A (no) |
IL (1) | IL113052A0 (no) |
MX (1) | MX9604026A (no) |
NO (1) | NO963806L (no) |
WO (1) | WO1995025805A1 (no) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001213773A (ja) * | 2000-01-31 | 2001-08-07 | Yaegaki Hakko Giken Kk | 高血圧および糖尿病改善剤とγ−アミノ酪酸の製造方法 |
ATE280590T1 (de) | 2000-05-23 | 2004-11-15 | Neurologix Inc | Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen |
US7695959B2 (en) * | 2000-05-23 | 2010-04-13 | Neurologix, Inc. | Glutamic acid decarboxylase (GAD) based delivery systems |
US20160136095A1 (en) * | 2014-11-18 | 2016-05-19 | PixarBio Corporation | Methods for treating epilepsy or seizure disorders |
WO2017123676A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8424757D0 (en) | 1984-10-01 | 1984-11-07 | Pasteur Institut | Retroviral vector |
FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
WO1987000201A1 (en) | 1985-07-05 | 1987-01-15 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
DE3855681T2 (de) | 1987-05-01 | 1997-05-28 | Gen Hospital Corp | Transkaryotische Einpflanzung |
DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Whitehead Biomedical Inst | Modifizierte hepatozyten und deren anwendung |
CA1315719C (en) | 1988-02-05 | 1993-04-06 | Arthur Bank | Retroviral packaging cell lines and processes of using same |
WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5270452A (en) * | 1988-11-28 | 1993-12-14 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Pure glia maturation factor |
JPH04507041A (ja) | 1988-12-13 | 1992-12-10 | アメリカ合衆国 | 遺伝工学により修飾された内皮細胞およびその利用方法 |
JP2814529B2 (ja) * | 1989-03-16 | 1998-10-22 | 味の素株式会社 | 虚血性脳障害治療薬 |
US5585362A (en) * | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
AU646877B2 (en) * | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
US6682906B1 (en) * | 1990-09-21 | 2004-01-27 | The Regents Of The University Of California | Cloned glutamic acid decarboxylase |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5189026A (en) * | 1991-06-07 | 1993-02-23 | Fractal Laboratories, Inc. | Treatment of human diseases involving dysregulation or dysfunction of the nervous system |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
SK283281B6 (sk) * | 1992-05-20 | 2003-05-02 | Northwestern University | Deriváty gamaaminomaslovej kyseliny, spôsoby a medziprodukty na ich výrobu, ich použitie a farmaceutické prostriedky |
JPH08501686A (ja) * | 1992-09-25 | 1996-02-27 | ローン−プーラン・ロレ・ソシエテ・アノニム | 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター |
FR2702152B1 (fr) * | 1993-03-03 | 1995-05-24 | Inst Nat Sante Rech Med | Virus recombinants et leur utilisation en thérapie génique. |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
FR2707664B1 (fr) | 1993-07-13 | 1995-09-29 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
-
1995
- 1995-03-20 IL IL11305295A patent/IL113052A0/xx unknown
- 1995-03-21 DE DE69534873T patent/DE69534873T2/de not_active Expired - Lifetime
- 1995-03-21 JP JP7524435A patent/JPH09511394A/ja active Pending
- 1995-03-21 AU AU21406/95A patent/AU2140695A/en not_active Abandoned
- 1995-03-21 AT AT95914389T patent/ATE320502T1/de not_active IP Right Cessation
- 1995-03-21 KR KR1019960705265A patent/KR100403893B1/ko not_active IP Right Cessation
- 1995-03-21 CA CA002184297A patent/CA2184297C/fr not_active Expired - Lifetime
- 1995-03-21 EP EP06004834A patent/EP1681354A3/fr not_active Withdrawn
- 1995-03-21 WO PCT/FR1995/000342 patent/WO1995025805A1/fr active Search and Examination
- 1995-03-21 MX MX9604026A patent/MX9604026A/es not_active IP Right Cessation
- 1995-03-21 EP EP95914389A patent/EP0752003B1/fr not_active Expired - Lifetime
- 1995-03-21 US US08/704,583 patent/US20020028212A1/en not_active Abandoned
-
1996
- 1996-09-11 NO NO963806A patent/NO963806L/no not_active Application Discontinuation
- 1996-09-20 FI FI963755A patent/FI963755A/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69534873D1 (de) | 2006-05-11 |
KR970701785A (ko) | 1997-04-12 |
NO963806D0 (no) | 1996-09-11 |
EP0752003A1 (fr) | 1997-01-08 |
FI963755A0 (fi) | 1996-09-20 |
CA2184297C (fr) | 2009-09-29 |
EP1681354A3 (fr) | 2010-08-11 |
KR100403893B1 (ko) | 2004-02-19 |
WO1995025805A1 (fr) | 1995-09-28 |
AU2140695A (en) | 1995-10-09 |
DE69534873T2 (de) | 2006-11-16 |
US20020028212A1 (en) | 2002-03-07 |
CA2184297A1 (fr) | 1995-09-28 |
MX9604026A (es) | 1997-09-30 |
JPH09511394A (ja) | 1997-11-18 |
IL113052A0 (en) | 1995-06-29 |
FI963755A (fi) | 1996-09-20 |
EP1681354A2 (fr) | 2006-07-19 |
ATE320502T1 (de) | 2006-04-15 |
EP0752003B1 (fr) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1394179T3 (da) | Fremgangsmåde til fremstilling af erythropoietin fri for animalske proteiner | |
ZA942778B (en) | Recombinant viruses, and their preparation and use in gene therapy. | |
CA2033176A1 (en) | Growth hormone fusion proteins | |
DK374689A (da) | Dna-sekvenser, som koder for polypeptider med beta-1,3-glucanaseaktivitet | |
EP1005376A4 (en) | METHODS AND COMPOSITIONS FOR USE IN GENE THERAPY IN THE TREATMENT OF HEMOPHILIA | |
NO993709L (no) | Stabilisert blanding omfattende fibrinogen | |
DE3786321T2 (de) | Expression von Protein-C. | |
AU3698697A (en) | Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament | |
ATE284954T1 (de) | Hyaluronan synthase gen und seine verwendung | |
DE3688900D1 (de) | Expression von protein c. | |
NO910982L (no) | Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller. | |
NO963806D0 (no) | Rekombinante viruser som koder for en glutamat-dekarboksylase (GAD)aktivitet | |
ATA3552000A (de) | Xylosyltransferase-gen | |
DE60036555D1 (de) | Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter | |
AU590861B2 (en) | New human lymphotoxin (TNF-beta) polypeptides their prepartion and use | |
EA200401390A1 (ru) | N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения | |
ES8605296A1 (es) | Procedimiento de producir factor viii-r humano | |
IL108584A0 (en) | Cloning of interferon - alpha beta binding protein | |
SE8901715L (sv) | En plasmid dna-konstruktion innehaallande dna-sekvenser | |
NO944878L (no) | Modifisert Kluyveromyces-gjær, dens fremstilling og anvendelse | |
EP0903147A3 (en) | Use of REG-2 as a Schwann cell mitogen | |
NO895154D0 (no) | Fremgangsmaate ved fremstilling av et protein eller polypeptid, en dna-sekvens som koder for polypeptidet, en mikroorganisme som inneholder dna-sekvensen samt polypeptidet ogdets anvendelse som et farmasoeytisk preparat. | |
NO941982L (no) | Fremstilling av proteiner ved anvendelse av 7B2 protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |